Battle In Hepatitis C Market: Bristol-Myers Squibb Needs To Speed Up

The market for Hepatitis C drugs is hot, thanks to Gilead Sciences’ breakthrough drug Sovaldi. The incredible financial incentive is encouraging other players such as Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ) and Merck (NYSE:MRK) to invest in R&D operations and grab a share of this growing market. Hepatitis C is a…

Read More